Recently, clinical data from a study evaluating the immunogenicity and safety of co-administered HPV and hepatitis E vaccines were published in Frontiers in Immunology.

On June 9, Consul General Mr. Sardar Muhammad of the Consulate General of Pakistan in Guangzhou led a delegation to visit Xiamen Innovax Biotech Co., Ltd. (IX). Harry Pan, General Manager of IX, together with representatives from Strategy & Business Development and International Business, received the delegation.

On June 5, 2026, a delegation led by Professor Lo Chung-mau, Secretary for Health of the Hong Kong Special Administrative Region, visited Xiamen Bio Bay and Xiamen Innovax Biotech Co., Ltd. (IX), accompanied by representatives from the Fujian Provincial Health Commission. The visit focused on biomedical innovation, vaccine R&D translation, clinical research collaboration, and international development.

Recently, the prequalification (PQ) application for Cecolin 9, the HPV 9-valent vaccine, was formally submitted to the World Health Organization (WHO). In accordance with relevant procedures, WHO will subsequently conduct dossier screening, technical assessment and manufacturing site inspection before making a final decision on whether to grant prequalification.

Recently, China Close-Up, a feature column by Xinhuanet, highlighted a standout case of Chinese HPV vaccine technology going globally, showcasing the collaboration among Xiamen Innovax Biotech Co., Ltd. (IX )， Thailand’s National Vaccine Institute (NVI), Chulalongkorn University and Global Biotech Products Co., Ltd. (GBP) in the field of HPV vaccines.

On January 27, 2026, Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. announced that its wholly owned subsidiary, Xiamen Innovax Biotech Co., Ltd. (“Innovax”), has maintained compliance with the World Health Organization (WHO) Prequalification (PQ) standards following a periodic re-inspection conducted by the WHO Prequalification Inspection Team (WHO PQT–INS) of its bivalent HPV vaccine, Cecolin. The vaccine was initially prequalified by WHO in 2021, and this re-inspection reaffirms its continued compliance with international quality standards.